BEAM Stock Cash Flow Statements

Beam Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Beam Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

operating activities
net income	-102,291,000	-109,270,000	-90,354,000	-96,668,000	-91,051,000	-98,669,000	142,797,000	-96,088,000	-82,776,000	-96,460,000	-38,349,000	-109,575,000	-71,950,000	-69,214,000	-64,707,000	-28,118,000	-76,253,000	-201,560,000	-95,464,000	-34,452,000	-34,218,000	-30,458,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	5,538,000	5,528,000	5,443,000	5,475,000	5,576,000	5,431,000	5,362,000	5,187,000	4,816,000	4,647,000	3,944,000	3,473,000	3,418,000	3,312,000	2,634,000	1,750,000	1,669,000	1,398,000
amortization of investment discount	-4,618,000	-3,849,000	-4,640,000	-5,623,000	-5,926,000	-6,576,000		-7,884,000	-7,573,000	-6,932,000	-5,102,000	-3,217,000	-701,000	-390,000	-47,000	-25,000	-18,000	15,000	69,000
stock-based compensation expense	24,367,000	26,682,000	30,218,000	29,559,000	31,604,000	29,281,000	22,617,000	25,835,000	26,278,000	23,917,000	22,499,000	22,209,000	21,578,000	18,035,000	15,502,000	12,968,000	10,452,000	4,648,000	6,807,000	3,012,000	2,769,000	2,792,000
change in operating lease right-of-use assets	2,648,000	2,649,000		2,438,000	2,394,000	2,361,000	2,402,000	2,288,000	2,475,000	2,354,000	2,193,000	2,143,000	2,097,000	1,997,000	2,209,000	2,147,000	2,275,000	2,359,000	1,672,000	1,080,000	1,033,000	952,000
change in fair value of derivative liabilities	-1,147,000	-2,260,000	128,000	200,000	-5,500,000	2,900,000	1,900,000	-4,700,000	900,000	-5,600,000	-3,000,000	4,900,000	-12,200,000	-13,600,000	-7,400,000	-35,800,000	42,300,000	1,900,000	54,700,000	-2,700,000	8,700,000	2,700,000
change in fair value of contingent consideration liabilities	28,000	27,000	27,000	27,000	-1,779,000	133,000	-1,863,000	-6,002,000	-2,171,000	296,000	-19,447,000	875,000	120,000	-452,000	4,407,000	-10,599,000	741,000	305,000
change in fair value of non-controlling equity investments	-4,415,000	2,081,000	1,090,000	2,064,000	7,586,000	3,353,000	722,000	11,221,000	-6,148,000	12,797,000	-21,578,000	-10,431,000	4,124,000	7,685,000	4,270,000	4,892,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	2,778,000	49,000	-7,807,000	1,744,000	6,246,000	-5,532,000	3,570,000	-3,567,000	1,929,000	-8,405,000	-561,000	-235,000	2,228,000	-9,185,000	13,000	3,839,000	-741,000	-2,365,000	-2,059,000	548,000	-656,000	-3,559,000
accounts payable	2,642,000	3,793,000	-550,000	-700,000	1,772,000	1,285,000	-1,768,000	-3,045,000	-2,534,000	-231,000	2,900,000	623,000	102,000	-1,252,000	2,159,000	-1,723,000	1,048,000	-666,000	194,000	-81,000	418,000	-471,000
accrued expenses and other liabilities	9,868,000	-18,458,000	-4,075,000	-9,849,000	-19,486,000	-24,275,000	70,401,000	7,416,000	-266,000	-9,888,000	8,443,000	3,938,000	-12,781,000	-16,533,000	41,096,000	1,171,000	6,105,000	-4,458,000	2,816,000	4,458,000	-617,000	378,000
operating lease liabilities	-3,325,000	-3,297,000	-3,275,000	-3,435,000	-3,133,000	-3,108,000	-3,007,000	-3,107,000	-1,504,000	-2,550,000	-1,066,000	1,151,000	14,125,000	-1,780,000	820,000	3,320,000	5,777,000	6,111,000	6,400,000	-1,448,000	-922,000	-879,000
deferred revenue	-8,466,000	-7,470,000	-5,067,000	-13,269,000	-11,272,000	-6,910,000	-99,543,000	-17,192,000	-19,116,000	-23,708,000	-20,037,000	-15,799,000	8,348,000	-8,432,000	298,932,000	-764,000
other long-term liabilities	-57,000	-89,000	22,000	-88,000	-40,000	579,000	-1,017,000	-146,000	1,021,000	-52,000	-30,000	-51,000	-10,784,000	8,296,000	1,942,000	-51,000	-45,000	-57,000	-1,094,000	2,087,000	-6,000	-6,000
net cash from operating activities	-76,450,000	-103,884,000	-76,365,000	-88,125,000	-83,009,000	-99,747,000	135,073,000	-89,784,000	-84,669,000	-109,815,000	-69,191,000	-74,496,000	-52,276,000	218,490,000	1,830,000	3,007,000	-32,527,000	-38,578,000	-24,298,000	-21,213,000	-22,837,000	-27,393,000
capex	-3,136,000	-3,065,000	-2,970,000	-1,577,000	-1,961,000	-2,438,000	-3,589,000	-7,948,000	-16,178,000	-6,017,000	-8,261,000	-11,787,000	-21,644,000	-7,259,000	-13,369,000	-5,780,000	-16,184,000	-11,478,000	-8,125,000	-2,819,000	-2,367,000	-3,046,000
free cash flows	-79,586,000	-106,949,000	-79,335,000	-89,702,000	-84,970,000	-102,185,000	131,484,000	-97,732,000	-100,847,000	-115,832,000	-77,452,000	-86,283,000	-73,920,000	211,231,000	-11,539,000	-2,773,000	-48,711,000	-50,056,000	-32,423,000	-24,032,000	-25,204,000	-30,439,000
investing activities
purchases of property and equipment	-3,136,000	-3,065,000	-2,970,000	-1,577,000	-1,961,000	-2,438,000	-3,589,000	-7,948,000	-16,178,000	-6,017,000	-8,261,000	-11,787,000	-21,644,000	-7,259,000	-13,369,000	-5,780,000	-16,184,000	-11,478,000	-8,125,000	-2,819,000	-2,367,000	-3,046,000
purchases of marketable securities	-333,942,000	-339,169,000	0	-156,725,000	-134,473,000	-195,241,000	-53,272,000	-273,707,000	-390,827,000	-266,532,000	-238,390,000	-358,031,000	-330,188,000	-690,390,000	-170,477,000	-178,500,000	-139,028,000	-289,218,000	-114,518,000	-31,135,000	-18,240,000	-117,719,000
maturities of marketable securities	166,667,000	217,145,000	129,250,000	183,000,000	223,927,000	144,215,000	154,960,000	271,425,000	365,525,000	298,000,000	360,090,000	333,644,000	350,570,000	160,310,000	106,350,000	260,395,000	142,075,000	20,450,000	41,216,000	69,182,000	43,475,000	44,723,000
net cash from investing activities	-170,411,000	-125,089,000	126,280,000	24,698,000	87,493,000	-53,464,000	98,099,000	-10,230,000	-41,480,000	25,451,000	113,439,000	-36,174,000	-1,262,000	-537,339,000	-77,496,000	76,115,000	-13,137,000	-279,626,000	-81,427,000	35,228,000	22,868,000	-76,792,000
financing activities
proceeds from issuance of common shares and pre-funded warrants, net of issuance costs	-646,000	471,159,000
proceeds from issuances of stock under espp	0	1,501,000	-1,000	1,224,000	0	1,398,000	0	1,324,000	0	1,708,000	-1,000	1,664,000	0	1,412,000
repayment of equipment financings				-201,000	-107,000	-177,000		-400,000	-617,000	-603,000	-590,000	-579,000	-565,000	-553,000	-542,000	-530,000	-517,000	-529,000	-411,000	-411,000	-432,000	-315,000
proceeds from exercise of stock options	1,755,000	719,000	3,445,000	239,000	240,000	1,676,000	745,000	1,292,000	702,000	3,392,000	764,000	502,000	646,000	820,000	1,969,000	2,702,000	3,197,000	1,758,000	2,086,000	557,000	360,000	152,000
net cash from financing activities	1,109,000	473,379,000	3,444,000	1,262,000	133,000	2,897,000	33,713,000	36,777,000	107,542,000	98,416,000	32,012,000	1,562,000	22,340,000	55,676,000	21,543,000	320,886,000	160,438,000	253,274,000	129,993,000	94,000	-779,000	193,014,000
net change in cash, cash equivalents and restricted cash	-245,752,000	244,406,000	53,359,000	-62,165,000	4,617,000	-150,314,000	266,885,000	-63,237,000	-18,607,000	14,052,000	76,260,000	-109,108,000	-31,198,000	-263,173,000		400,008,000	114,774,000	-64,930,000		14,109,000	-748,000	88,829,000
cash, cash equivalents and restricted cash—beginning of period	0	290,111,000	0	0	0	444,614,000	0	0	0	245,521,000	0	0	0	572,740,000	0	0	0	177,011,000	0	0	0	50,553,000
cash, cash equivalents and restricted cash—end of period	-245,752,000	534,517,000	53,359,000	-62,165,000	4,617,000	294,300,000	266,885,000	-63,237,000	-18,607,000	259,573,000	76,260,000	-109,108,000	-31,198,000	309,567,000	-54,123,000	400,008,000	114,774,000	112,081,000	24,268,000	14,109,000	-748,000	139,382,000
income from equity method investment											0
amortization of operating lease right-of-use assets
other											0	0	0	3,000	0	0	1,039,000	-976,000	0	0
collaboration receivable											0	0	0	300,000,000
proceeds from issuance of common shares, net of commissions							0	34,945,000	107,642,000	93,981,000	31,893,000	0	22,362,000	54,003,000	20,244,000	318,923,000
payment of equity offering costs							0	-384,000	-185,000	-62,000	-54,000	-25,000	-103,000	-6,000		-209,000	-524,000	-7,955,000
equipment financings
proceeds from private stock issuance
amortization of investment (discount) premiums
in-process research and development charge															0	0	0	154,953,000
other long-term assets															0	0	-12,000	-185,000	-98,000	12,000	9,000	-77,000
net cash acquired from guide															0	0	0	620,000
non-cash research and development license expense																			487,000	4,900,000	0	264,000
purchase of non-controlling equity investment
proceeds from initial public offering, net of underwriting discount																			0	0	0	192,510,000
proceeds from october 2020 public offering, net of underwriting discount
proceeds from equipment financings																			1,642,000	0	0	1,625,000
financing milestone liabilities
proceeds from issuance of series b preferred stock
payment of initial and follow-on equity offering costs
net increase in cash, cash equivalents and restricted cash
purchase of long-term investment																			0	0	0	-750,000
proceeds from offering of common stock																		260,000,000
depreciation																			1,272,000	1,218,000	1,145,000	1,100,000
payment of initial and follow-on public offering costs																			-342,000
net increase in in cash, cash equivalents and restricted cash
amortization of investment premiums																					25,000	-129,000
payment of initial public offering costs																					-707,000	-958,000
supplemental disclosure of cash flow information:
cash paid for interest																					148,000	134,000
supplemental disclosure of noncash investing and financing activities:
conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering																					0	303,326,000
property and equipment additions in accounts payable and accrued expenses																					-285,000	1,032,000
operating lease liabilities arising from obtaining right-of-use assets																					1,763,000	4,032,000
receipt of common stock in exchange for technology license
issuance of common stock for research and development license
equity issuance costs in accounts payable and accrued expenses																						707,000
accretion of redeemable convertible preferred stock to redemption value, including dividends on preferred stock																					0	1,277,000
loss on issuance of preferred stock in connection with blink merger
loss on issuance of preferred stock to investors
change in fair value of preferred stock tranche liabilities
deferred rent liabilities
proceeds from issuance of series a-1 preferred stock
proceeds from issuance of series a-2 preferred stock
proceeds from issuance of blink series a preferred stock
equity issuance costs
issuance of common stock in connection with blink merger
issuance of common stock to founders in connection with blink merger
issuance of series a-2 preferred stock in connection with blink merger
issuance of series a-1 and a-2 preferred stock for research and development license
recognition and derecognition of preferred stock tranche liabilities

We provide you with 20 years of cash flow statements for Beam Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Beam Therapeutics stock. Explore the full financial landscape of Beam Therapeutics stock with our expertly curated income statements.

The information provided in this report about Beam Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.